VJHemOnc is committed to improving our service to you

SOHO 2020 | Future of the lymphoma field

VJHemOnc is committed to improving our service to you

Loretta Nastoupil

Loretta Nastoupil, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the evolving treatment landscape of lymphoma, including recent data evaluating allogeneic CAR T-cells in the relapsed/refractory setting. Furthermore, the development of novel targeted agents such as tafasitamb, as evaluated in the Phase II L-MIND study (NCT02399085), represents an exciting approach in the lymphoma field. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter